BrainChip Holdings has wrapped up its capital management arrangement with LDA Capital, settling a $1 million failure fee through collateral share sales and preparing for orderly liquidation of remaining shares.
- LDA Put Option Agreement expired 30 June 2026
- $1 million failure fee settled with collateral shares
- Approximately 6.96 million shares sold for fee payment
- LDA to liquidate remaining 6 million shares orderly
- Net proceeds after 8.5% fee to be remitted to BrainChip
Expiration of Capital Facility Marks End of Financing Arrangement
BrainChip Holdings Ltd (ASX:BRN) has officially closed its Put Option Agreement with LDA Capital Limited, which expired on 30 June 2026. This facility had provided BrainChip with flexible capital management options during its term but is now fully concluded, removing this source of financial flexibility from the company’s toolkit.
Failure Fee Settled Through Collateral Share Sales
As part of the agreement’s terms, BrainChip faced a failure fee obligation of A$1 million triggered by certain conditions. Rather than a cash payment, this fee was satisfied by LDA selling approximately 6.96 million BrainChip shares held as collateral. The gross proceeds from these sales were applied entirely to discharge the fee, effectively settling the company’s outstanding obligations under the agreement without tapping into its cash reserves.
Remaining Collateral Shares to Be Sold Carefully
Following the fee-related share sales, LDA still holds about 6 million collateral shares. The company has been informed that LDA intends to liquidate these shares over the coming weeks in an orderly fashion designed to minimise disruption to BrainChip’s share price. The net proceeds from this liquidation, after deducting LDA’s standard 8.5% fee, will be returned to BrainChip.
Closing Out Without Cash Impact
BrainChip emphasised that resolving the failure fee and collateral arrangements through share sales allowed a clean end to the facility without drawing on company cash. This is a notable outcome given the company’s ongoing investments in its neuromorphic AI platform, including recent progress with the AKD1500 chip and strategic partnerships in defence and industrial sectors.
What Comes Next for BrainChip’s Capital Structure
With the facility closed and collateral shares being liquidated, BrainChip’s capital structure will soon reflect this unwinding. Investors will be watching how the remaining share sales impact market liquidity and share price in the short term. The company has committed to updating the market once the liquidation completes and net proceeds are received, marking the final chapter of this financing arrangement.
Bottom Line?
BrainChip’s expiration of the LDA facility and collateral liquidation closes a chapter on flexible financing, but the timing and impact of remaining share sales warrant close attention.
Questions in the middle?
- How will the orderly liquidation of remaining collateral shares affect BrainChip’s share price in the near term?
- What alternative capital management strategies will BrainChip pursue now that this facility has ended?
- Will the conclusion of this arrangement free up resources to accelerate development of BrainChip’s Akida AI platform?